Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo.

International journal of pharmaceutics

Volumn 456, Issue 1, 2013, Pages 243-250

  Tang, Xin Jiang ^a   Fu, Ying Hua ^b   Meng, Qing Hua ^b   Li, Li Ming ^b   Ying, Xiao Ying ^b   Han, Min ^b   He, Qiao Jun ^b   Yang, B ^b   Zeng, S ^b   Hu, Yong Zhou ^b   Sheng, Xiao Xia ^b   Gao, Jian Qing ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3-(4-BROMOPHENYL)-2-(ETHYLSULFONYL)-6-METHYLQUINOXALINE-1,4-DIOXIDE; ANTINEOPLASTIC AGENT; NANOPARTICLE; POLOXAMER; QUINOXALINE DERIVATIVE; SURFACTANT; SUSPENSION;

ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; HEPG2 CELL LINE; HUMAN; MALE; MOUSE; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PRESSURE; SOLUBILITY; SUSPENSION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; DRUG STABILITY; HEP G2 CELLS; HUMANS; MALE; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; POLOXAMER; PRESSURE; QUINOXALINES; SOLUBILITY; SURFACE-ACTIVE AGENTS; SUSPENSIONS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896037840     PISSN: None     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.07.058     Document Type: Article

References (39)

1. H.S. Ali P. York N. Blagden Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors Int. J. Pharm. 375 2009 107 113
2. F. Artzner S. Geiger A. Olivier C. Allais S. Finet F. Agnely Interactions between poloxamers in aqueous solutions: micellization and gelation studied by differential scanning calorimetry, small angle X-ray scattering, and rheology Langmuir 23 2007 5085 5092
3. Y. Chen J. Liu X. Yang X. Zhao H. Xu Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect J. Pharm. Pharmacol. 57 2005 259 264
4. J. Chingunpituk Nanosuspension technology for drug delivery Walailak J. Sci. Technol. 4 2007 139 153
5. J.Y. Choi C.H. Park J. Lee Effect of polymer molecular weight on nanocomminution of poorly soluble drug Drug Deliv. 15 2008 347 353
6. P.P. Constantinides M.V. Chaubal R. Shorr Advances in lipid nanodispersions for parenteral drug delivery and targeting Adv. Drug Deliv. Rev. 60 2008 757 767
7. B. De Gioannis P. Jestin P. Subra Morphology and growth control of griseofulvin recrystallized by compressed carbon dioxide as antisolvent J. Cryst. Growth 262 2004 519 526
8. R.T. Dorr Pharmacology and toxicology of Cremophor EL diluent Ann. Pharmacother. 28 1994 S11 S14
9. M.G. Fakes B.J. Vakkalagadda F. Qian S. Desikan R.B. Gandhi C. Lai A. Hsieh M.K. Franchini H. Toale J. Brown Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches Int. J. Pharm. 370 2009 167 174
10. C. Freitas R.H. Müller Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions Int. J. Pharm. 168 1998 221 229
11. L. Gao D. Zhang M. Chen C. Duan W. Dai L. Jia W. Zhao Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions Int. J. Pharm. 355 2008 321 327
12. Y. Gao Z. Li M. Sun C. Guo A. Yu Y. Xi J. Cui H. Lou G. Zhai Preparation and characterization of intravenously injectable curcumin nanosuspension Drug Deliv. 18 2011 131 142
13. L. Gao G. Liu J. Ma X. Wang L. Zhou X. Li Drug nanocrystals: in vivo performances J. Control. Release 160 2012 418 430
14. L. Hao X. Wang D. Zhang Q. Xu S. Song F. Wang C. Li H. Guo Y. Liu D. Zheng Q. Zhang Studies on the preparation, characterization and pharmacokinetics of Amoitone B nanocrystals Int. J. Pharm. 433 2012 157 164
15. T. Heimbach D. Fleisher A. Kaddoumi Overcoming poor aqueous solubility of drugs for oral delivery Biotechnol. Pharm. Aspects 5 2007 157 215
16. L.D. Irizarry T. Ha Luu J.M. McKoy A.T. Samaras M.J. Fisher E.E. Carias D.W. Raisch E.A. Calhoun C.L. Bennett Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action Comm. Oncol. 6 2009 132 134
17. C. Jacobs R.H. Muller Production and characterization of a budesonide nanosuspension for pulmonary administration Pharm. Res. 19 2002 189 194
18. J. Jinno N. Kamada M. Miyake K. Yamada T. Mukai M. Odomi H. Toguchi G.G. Liversidge K. Higaki T. Kimura Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs J. Control. Release 111 2006 56 64
19. P. Kayaert G. Van den Mooter Is the amorphous fraction of a dried nanosuspension caused by milling or by drying? A case study with Naproxen and Cinnarizine Eur. J. Pharm. Biopharm. 81 2012 650 656
20. C.M. Keck R.H. Muller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur. J. Pharm. Biopharm. 62 2006 3 16
21. J. Liebmann J.A. Cook J.B. Mitchell Cremophor EL, solvent for paclitaxel, and toxicity Lancet 342 1993 1428
22. H. Lou X. Zhang L. Gao F. Feng J. Wang X. Wei Z. Yu D. Zhang Q. Zhang In vitro and in vivo antitumor activity of oridonin nanosuspension Int. J. Pharm. 379 2009 181 186
23. S.A. Maskarinec J. Hannig C.L. Raphael C.L. Ka Yee Direct observation of poloxamer188 insertion into lipid monolayers Biophys. J. 82 2002 1453 1459
24. E.M. Merisko-Liversidge G.G. Liversidge Drug nanoparticles: formulating poorly water-soluble compounds Toxicol. Pathol. 36 2008 43 48
25. J. Moschwitzer G. Achleitner H. Pomper R.H. Muller Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology Eur. J. Pharm. Biopharm. 58 2004 615 619
26. R.H. Muller C.M. Keck Challenges and solutions for the delivery of biotech drugs–a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 113 2004 151 170
27. V.B. Patravale A.A. Date R.M. Kulkarni Nanosuspensions: a promising drug delivery strategy J. Pharm. Pharmacol. 56 2004 827 840
28. R. Pignatello C. Bucolo P. Ferrara A. Maltese A. Puleo G. Puglisi Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen Eur. J. Pharm. Sci. 16 2002 53 61
29. B.E. Rabinow Nanosuspensions in drug delivery Nat. Rev. Drug Discov. 3 2004 785 796
30. B. Rabinow J. Kipp P. Papadopoulos J. Wong J. Glosson J. Gass C.S. Sun T. Wielgos R. White C. Cook K. Barker K. Wood Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat Int. J. Pharm. 339 2007 251 260
31. R. Shegokar K.K. Singh Surface modified nevirapine nanosuspensions for viral reservoir targeting: in vitro and in vivo evaluation Int. J. Pharm. 421 2011 341 352
32. R. Sheng Y. Xu Q.J. Weng Q. Xia Q.J. He B. Yang Y.Z. Hu Synthesis and cytotoxic activity of 3-phenyl-2-thio-quinoxaline 1,4-dioxide derivatives in hypoxia and in normoxia Drug Discov. Ther. 1 2007 119 123
33. M.L. Tsai L.Z. Tseng R.H. Chen Two-stage microfluidization combined with ultrafiltration treatment for chitosan mass production and molecular weight manipulation Carbohydr. Polym. 77 2009 767 772
34. J.L. Wahlstrom P.-C. Chiang S. Ghosh C.J. Warren S.P. Wene L.A. Albin Mark E. Smith S.L. Roberds Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment Nanoscale Res. Lett. 2 2007 291 296
35. Q. Weng D. Wang P. Guo L. Fang Y. Hu Q. He B. Yang Q39, a novel synthetic quinoxaline 1,4-di-N-oxide compound with anti-cancer activity in hypoxia Eur. J. Pharmacol. 581 2008 262 269
36. H. Zhang C.P. Hollis Q. Zhang T. Li Preparation and antitumor study of camptothecin nanocrystals Int. J. Pharm. 415 2011 293 300
37. Y.X. Zhao H.Y. Hua M. Chang W.J. Liu Y. Zhao H.M. Liu Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions Int. J. Pharm. 392 2010 64 71
38. D. Zheng Y. Wang D. Zhang Z. Liu C. Duan L. Jia F. Wang Y. Liu G. Liu L. Hao Q. Zhang In vitro antitumor activity of silybin nanosuspension in PC-3 cells Cancer Lett. 307 2011 158 164
39. A. Zimmermann A. Millqvist-Fureby M.R. Elema T. Hansen A. Mullertz L. Hovgaard Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties Eur. J. Pharm. Biopharm. 71 2009 109 116